Trinity Biotech PLC logo

Trinity Biotech PLC - ADR

FRA:TRB (Ireland)   ADR
€ 2.12 (0%) May 14
At Loss
Market Cap:
€ 20.08M ($ 21.85M)
Enterprise V:
€ 78.95M ($ 85.91M)
Volume:
-
Avg Vol (2M):
-
Also Trade In:
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Trinity Biotech PLC ( ) from 1990 to May 15 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Trinity Biotech PLC stock (FRA:TRB) PE ratio as of May 15 2024 is 0. More Details

Trinity Biotech PLC (FRA:TRB) PE Ratio (TTM) Chart

To

Trinity Biotech PLC (FRA:TRB) PE Ratio (TTM) Historical Data

Total 1274
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 15
Trinity Biotech PLC PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-05-16 At Loss 2024-03-13 At Loss
2024-05-14 At Loss 2024-03-12 At Loss
2024-05-13 At Loss 2024-03-11 At Loss
2024-05-10 At Loss 2024-03-08 At Loss
2024-05-09 At Loss 2024-03-07 At Loss
2024-05-08 At Loss 2024-03-06 At Loss
2024-05-07 At Loss 2024-03-05 At Loss
2024-05-06 At Loss 2024-03-04 At Loss
2024-05-03 At Loss 2024-03-01 At Loss
2024-05-02 At Loss 2024-02-29 At Loss
2024-05-01 At Loss 2024-02-28 At Loss
2024-04-30 At Loss 2024-02-27 At Loss
2024-04-29 At Loss 2024-02-26 At Loss
2024-04-26 At Loss 2024-02-23 At Loss
2024-04-25 At Loss 2024-02-22 At Loss
2024-04-24 At Loss 2024-02-21 At Loss
2024-04-23 At Loss 2024-02-20 At Loss
2024-04-22 At Loss 2024-02-19 At Loss
2024-04-19 At Loss 2024-02-16 At Loss
2024-04-18 At Loss 2024-02-15 At Loss
2024-04-17 At Loss 2024-02-14 At Loss
2024-04-16 At Loss 2024-02-13 At Loss
2024-04-15 At Loss 2024-02-12 At Loss
2024-04-12 At Loss 2024-02-09 At Loss
2024-04-11 At Loss 2024-02-08 At Loss
2024-04-10 At Loss 2024-02-07 At Loss
2024-04-09 At Loss 2024-02-06 At Loss
2024-04-08 At Loss 2024-02-05 At Loss
2024-04-05 At Loss 2024-02-02 At Loss
2024-04-04 At Loss 2024-02-01 At Loss
2024-04-03 At Loss 2024-01-31 At Loss
2024-04-02 At Loss 2024-01-30 At Loss
2024-04-01 At Loss 2024-01-29 At Loss
2024-03-29 At Loss 2024-01-26 At Loss
2024-03-28 At Loss 2024-01-25 At Loss
2024-03-27 At Loss 2024-01-24 At Loss
2024-03-26 At Loss 2024-01-23 At Loss
2024-03-25 At Loss 2024-01-22 At Loss
2024-03-22 At Loss 2024-01-19 At Loss
2024-03-21 At Loss 2024-01-18 At Loss
2024-03-20 At Loss 2024-01-17 At Loss
2024-03-19 At Loss 2024-01-16 At Loss
2024-03-18 At Loss 2024-01-15 At Loss
2024-03-15 At Loss 2024-01-12 At Loss
2024-03-14 At Loss 2024-01-11 At Loss

Trinity Biotech PLC (FRA:TRB) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Trinity Biotech PLC logo
Trinity Biotech PLC
NAICS : 325413 SIC : 2835
ISIN : US8964383066

Share Class Description:

FRA:TRB: ADR
Description
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.